Free Trial
NASDAQ:BMEA

Biomea Fusion Q1 2024 Earnings Report

Biomea Fusion logo
$1.86 +0.03 (+1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$1.86 +0.00 (+0.22%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion EPS Results

Actual EPS
-$1.09
Consensus EPS
-$1.02
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Biomea Fusion Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomea Fusion Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 2, 2024
Conference Call Time
4:05PM ET

Upcoming Earnings

Biomea Fusion's Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled on Tuesday, October 28, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Biomea Fusion Earnings Headlines

Biomea Fusion (BMEA) Gets a Buy from Oppenheimer
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Biomea Fusion (BMEA) Q2 Loss Drops 44%
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

View Biomea Fusion Profile

More Earnings Resources from MarketBeat